DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2MO AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2MO AGO
Live database · updated 2mo ago

The honest source
for peptide intelligence.

Evidence-graded research on every peptide in the database, verified COA records, live regulatory status, and an AI that cites its sources — not yours from 2023.

100+
Compounds tracked
2,000+
PubMed citations
45
Grade A evidence
11
Research vendors
AB
A
Semaglutide
FDA approved
C
BPC-157
Animal-only evidence
PubMed-indexed
Every claim cited
01 · The platform

One database.
Four surfaces to use it.

We built a proprietary research pipeline — PubMed, FDA, ClinicalTrials.gov, and expert curation — and expose it through the tools you actually need.

Primary

AI chat, grounded in our database

RAG-powered chat retrieves from live pgvector data, not training-cutoff guesses. Every claim is cited to a PubMed ID.

› What does the research say about BPC-157?
Evidence grade C — the literature is almost entirely rodent tissue-repair work; no completed human RCTs.PubMed cited
Grade CLive from DB
02

100+ compound pages, evidence-graded

A through D based on human RCTs. No vendor claims. No influencer scripts.

A
SemaglutideFDA approved
A
TirzepatideFDA approved
B
IpamorelinRx compounded
03

Clinic & vendor finder

10 real, publicly-operating clinics and 11 research vendors — verified licensure, posted pricing only.

Empower Pharmacy
NATIONWIDE · 503A / 503B
LICENSED
CONTACT FOR PRICING·RX REQUIRED
04

Mobile tracker with COA scan

Dose log, reconstitution math, body map, and Claude-vision COA verification in your pocket.

9:41●●●
TODAY · TUE
3 doses
scheduled
Semaglutide · 0.5mg8:00 AM
BPC-157 · 250mcg2:00 PM
02 · Why not just ask ChatGPT

ChatGPT's training data ended before peptides went mainstream.

Question
Peptidebase
ChatGPT · Generic LLM
Latest FDA ruling on a compound
Pulled from fda.gov with the date it was issued.
Training cutoff: often silent or out of date.
BPC-157 evidence grade
C — animal only. States the uncertainty.
Confident, uncited claims.
Is this compound still legal to compound?
Live 503A/503B status with source link.
Stale. Often confuses Category 1 vs 2.
Current Phase 3 trial status
Pulled from ClinicalTrials.gov with NCT ID.
Data frozen. No live trials.
Peer-reviewed citations for a claim
Every claim links to a real PubMed ID.
Plausible-sounding but uncited.
03 · Methodology

Every compound gets a letter grade.

Adapted from the Oxford Centre for Evidence-Based Medicine. We'd rather say “we don't know” than fake confidence.

A
45
compounds
Multiple human RCTs

Consistent findings across ≥2 randomized controlled trials in humans. The standard most pharmaceutical drugs meet.

Typical examples
SemaglutideTirzepatideTesamorelin
B
30
compounds
At least one human study

One observational or single RCT in humans. Promising but not yet conclusive.

Typical examples
IpamorelinCJC-1295Sermorelin
C
25
compounds
Animal studies only

Rodent or other non-human evidence. Mechanism plausible, translation to humans unproven.

Typical examples
BPC-157TB-500Epithalon
D
2
compounds
In vitro or no evidence

Cell-culture data only, or essentially no meaningful research. Buyer beware.

Typical examples
DihexaFGLPinealon
04 · Regulatory tracker

Peptide law changes often.
We keep it current.

Every FDA ruling, state-level restriction, and compounding category change — sourced from fda.gov, federalregister.gov, and public enforcement records. Pro users get email alerts when a compound on their regimen is affected.

See the live tracker
Latest events
  • Shortage statusFEB 21 · 2025
    FDA declares semaglutide shortage resolved
  • FDA · CompoundingJAN 09 · 2025
    FDA issues final rule on 503A bulk drug substance list
  • FDA · ApprovalDEC 20 · 2024
    FDA approves Zepbound (tirzepatide) for obstructive sleep apnea
05 · Featured compounds

Research-graded,
not vendor-hyped.

View all 100+
A
Semaglutide
GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
CategoryGLP-1 · metabolic
Papers indexed31
Human studies29
A
Corticotropin (ACTH)
Porcine pituitary-derived ACTH gel used as an anti-inflammatory agent in specific steroid-responsive conditions.
CategoryPeptide
Papers indexed30
Human studies25
A
Desmopressin
Synthetic vasopressin analog used for diabetes insipidus, nocturnal enuresis, and mild hemophilia A / von Willebrand disease.
CategoryPeptide
Papers indexed30
Human studies24
A
Lonapegsomatropin
Once-weekly pegylated prodrug of somatropin that releases unmodified hGH over a week.
CategoryGrowth hormone axis
Papers indexed30
Human studies25
06 · AI chat

Ask anything.
Cited answers.

Every response pulls from our live database — 2,000+ PubMed citations across 100+ compound records, plus current FDA status. No hallucinated brand names. No 2023 answers.

150–300 word replies Citations on every claim
Peptidebase ChatLive database
claude-sonnet · rag
What does the human-trial evidence actually say about BPC-157?

Short answer: almost none. The literature is dominated by rodent tissue-repair studies. We grade BPC-157 as C — animal studies only.

No completed human randomized trials have been indexed. Claims on human outcomes are extrapolations; treat them accordingly.

PubMed citedGrade CAnimal evidence

Educational information only — consult a licensed provider.

07 · Pricing

Free to browse.
Pro for power users.

Free
$0
forever, no card
Browse free
  • All 100+ compound pages
  • 3 AI chat messages / day
  • Reconstitution calculator
  • Clinic & vendor directory
Most popular
Pro
$14.99
/mo
or $99/year · save 45%
Start 14-day trial
  • Unlimited AI chat
  • Mobile app (iOS + Android)
  • COA scanner w/ Claude vision
  • Regulatory email alerts
  • Dose tracker + calendar sync
  • Priority new compound requests

Built for people who read the paper, not just the headline.

Peptides are going mainstream fast. The information ecosystem has not kept up. We're fixing that.